What is the real impact of the change in the screening strategy for cervical cancer in Brazil?
DOI:
https://doi.org/10.5327/DST-2177-8264-2024361413Abstract
n March 11, 2024, the Brazilian Ministry of Health approved the HPV-DNA test for cervical cancer screening through the National Commission for the Incorporation of Technologies in the Unified Health System (CONITEC). This development immediately raises several questions. What will the strategy be in Brazil when we transition to HPV DNA testing? Will there be a significant reduction in the number of cervical cancers? Undoubtedly, the challenge is substantial. There are many tests available. What will be the criteria for choosing the test? Which genotypes will be identified? Is it consistent with the local reality? In any case, new tools are always welcome and should be pursued. However, we must be careful not to create high expectations in a system before there is assurance and understanding that it will provide more significant and better benefits for the populations involved in the short and long-term.Downloads
References
Brasil. Ministério da Saúde. Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde. Prevenção de câncer de colo de útero: Ministério da Saúde incorpora teste inovador para detecção do HPV em mulheres [Internet]. [cited on 2024 Mar 16]. Available from: https://www.gov.br/conitec/pt-br/assuntos/noticias/2024/marco/prevencao-de-cancer-de-colo-de-utero-ministerio-da-saude-incorpora-teste-inovador-para-deteccao-do-hpv-em-mulheres
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Incidência [Internet]. [cited on 2024 Mar 16]. Available from: https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-do-cancer-do-colo-do-utero/dados-e-numeros/incidencia/incidencia
Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8(8):CD008587. https://doi.org/10.1002/14651858.CD008587.pub2
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. [cited on 2024 Mar 16]. Available from: https://iris.who.int/bitstream/handle/10665/336583/9789240014107-eng.pdf?sequence=1
Carvalho CF, Teixeira JC, Bragança JF, Derchain S, Zeferino LC, Vale DB. Rastreamento do câncer do colo do útero com teste de DNA-HPV: atualizações na recomendação. Femina. 2022;50(4):200-7.
Speck NMG, Carvalho JP. Dossiê de estratégias do rastreamento do câncer de colo uterino no Brasil [Internet]. [cited on 2024 Mar 16]. Available from: https://www.febrasgo.org.br/pt/noticias/item/download/167_d8aac29103a80d079e7031cf127c72d6
Chua BWB, Ma VY, Alcántar-Fernández J, Wee HL. Is it time to genotype beyond HPV16 and HPV18 for cervical cancer screening? Int J Public Health. 2022;67:1604621. https://doi.org/10.3389/ijph.2022.1604621
Monteiro JC, Tsutsumi MY, Carvalho DO, Costa ECS, Feitosa RNM, Laurentino RV, et al. Prevalence, diversity, and risk factors for cervical HPV infection in women screened for cervical cancer in Belem, Para, Northern Brazil. Pathogens. 2022;11(9):960. https://doi.org/10.3390/pathogens11090960
Wendland EM, Villa LL, Unger ER, Domingues CM, Benzaken AS; POP-Brazil Study Group. Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: the POP-Brazil study. Sci Rep. 2020;10(1):4920. https://doi.org/10.1038/s41598-020-61582-2
Eleutério J Jr, Sobreira SRD, Teixeira MS, Bezerra ED. Colo uterino: rastreio com autocoleta é seguro e viável? Revista Brasileira de Patologia do Trato Genital Inferior. 2022;7(1):24-7.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Sexually Transmitted Diseases
This work is licensed under a Creative Commons Attribution 4.0 International License.
